CVS HEALTH
CVS· Retail Trade· Fiscal year ends in December
J. David Joyner is the CEO of CVS HEALTH and was paid $21.2M in FY2025 (Dec), up 19%.
Executives6
See all- 1J. David JoynerPresident and Chief Executive OfficerFY2025
- 2Prem S. ShahExecutive Vice President and Group PresidentFY2025
- 3Steven H. NelsonExecutive Vice President and President, AetnaFY2025
- 4Tilak MandadiExecutive Vice President Ventures, and Chief Digital, Data, Analytics and Technology OfficerFY2025
- 5Brian O. NewmanExecutive Vice President and Chief Financial OfficerFY2025
- 6Thomas F. CowheyExecutive Vice President and Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCVS HEALTH paid its 6 named executives $73.3M in total in FY2025 (Dec). CEO J. David Joyner was paid $21.2M of that.
| Name | |||
|---|---|---|---|
| J. David JoynerPresident and Chief Executive Officer | Not disclosed | ||
| Prem S. ShahExecutive Vice President and Group President | |||
| Steven H. NelsonExecutive Vice President and President, Aetna | Not disclosed | Not disclosed | |
| Tilak MandadiExecutive Vice President Ventures, and Chief Digital, Data, Analytics and Technology Officer | |||
| Brian O. NewmanExecutive Vice President and Chief Financial Officer | Not disclosed | Not disclosed | |
| Thomas F. CowheyExecutive Vice President and Chief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe FY2025 (Dec) proxy of CVS HEALTH names 19 peer companies for pay. Among CVS HEALTH and these peers, CEO pay was 13th highest of 18 and total shareholder return was 11th highest of 18.
13th highest of 18in CVS HEALTH and its pay peers, FY2025 (Dec) by CEO pay:
11th highest of 18in CVS HEALTH and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Insider trades3
See allInsiders sold $13.2M of stock in the 12 months before the latest trade.
| Jun 28, 2022 | Moriarty Thomas MEVP & General Counsel | Sold | 7.3% | Not stated | ||
| Jun 28, 2022 | Moriarty Thomas MEVP & General Counsel | Sold | 7.5% | Not stated | ||
| Jun 28, 2022 | Moriarty Thomas MEVP & General Counsel | Sold | 5.8% | Not stated |
Open-market buys and sales from Form 4. A plan trade is marked .
Board4
See all- Anne M. FinucaneDirector · 13 yr on the boardIndependentAudit, Executive, Management Planning and Development—Paid as an executive
- Fernando AguirreDirector · 6 yr on the boardIndependentAudit (Chair), Management, Planning and Development—Paid as an executive
- J. David JoynerDirector · 0 yr on the boardNot independentExecutive—Paid as an executive
- Leslie V. NorwalkDirector · 0 yr on the boardNot independentHealth Services and Technology—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings138
See all| Current report | 8-K | Aug 17, 2026 | — |
| Current report | 8-K | May 18, 2026 | — |
| Proxy statement | DEF 14A | Apr 3, 2026 | FY2025 |
| Current report | 8-K | Mar 19, 2026 | — |
| Annual report | 10-K | Feb 10, 2026 | FY2025 |
| Insider trade (Form 4) | 4 | Nov 21, 2025 | — |
